A Preclinical Model of Malignant Peripheral Nerve Sheath Tumor-like Melanoma Is Characterized by Infiltrating Mast Cells.

Human melanomas exhibit considerable genetic, pathologic, and microenvironmental heterogeneity. Genetically engineered mice have successfully been used to model the genomic aberrations contributing to melanoma pathogenesis, but their ability to recapitulate the phenotypic variability of human disease and the complex interactions with the immune system have not been addressed. Here, we report the unexpected finding that immune cell-poor pigmented and immune cell-rich amelanotic melanomas developed simultaneously in Cdk4R24C-mutant mice upon melanocyte-specific conditional activation of oncogenic BrafV600E and a single application of the carcinogen 7,12-dimethylbenz(a)anthracene. Interestingly, amelanotic melanomas showed morphologic and molecular features of malignant peripheral nerve sheath tumors (MPNST). A bioinformatic cross-species comparison using a gene expression signature of MPNST-like mouse melanomas identified a subset of human melanomas with a similar histomorphology. Furthermore, this subset of human melanomas was found to be highly associated with a mast cell gene signature, and accordingly, mouse MPNST-like melanomas were also extensively infiltrated by mast cells and expressed mast cell chemoattractants similar to human counterparts. A transplantable mouse MPNST-like melanoma cell line recapitulated mast cell recruitment in syngeneic mice, demonstrating that this cell state can directly reconstitute the histomorphologic and microenvironmental features of primary MPNST-like melanomas. Our study emphasizes the importance of reciprocal, phenotype-dependent melanoma-immune cell interactions and highlights a critical role for mast cells in a subset of melanomas. Moreover, our BrafV600E-Cdk4R24C model represents an attractive system for the development of therapeutic approaches that can target the heterogeneous tumor microenvironment characteristic of human melanomas.

[1]  S. Aerts,et al.  Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state , 2015, Nature Communications.

[2]  H. Møller,et al.  MelanA-negative spindle-cell associated melanoma, a distinct inflammatory phenotype correlated with dense infiltration of CD163 macrophages and loss of E-cadherin , 2015, Melanoma research.

[3]  Johan Staaf,et al.  Molecular stratification of metastatic melanoma using gene expression profiling : Prediction of survival outcome and benefit from molecular targeted therapy , 2015, Oncotarget.

[4]  T. Graeber,et al.  MITF drives endolysosomal biogenesis and potentiates Wnt signaling in melanoma cells , 2015, Proceedings of the National Academy of Sciences.

[5]  D. Peeper,et al.  Phenotype switching: tumor cell plasticity as a resistance mechanism and target for therapy. , 2014, Cancer research.

[6]  Michael Hölzel,et al.  Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. , 2014, Cancer discovery.

[7]  J. Mesirov,et al.  A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. , 2014, Cancer discovery.

[8]  D. Schadendorf,et al.  Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma , 2014, Nature.

[9]  Theresa Guo,et al.  A Polymorphism in IRF4 Affects Human Pigmentation through a Tyrosinase-Dependent MITF/TFAP2A Pathway , 2013, Cell.

[10]  J. Brandner,et al.  TGF‐β1 and TNF‐α differentially regulate Twist1 mediated resistance towards BRAF/MEK inhibition in melanoma , 2013, Pigment cell & melanoma research.

[11]  Z. Trajanoski,et al.  Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.

[12]  J. Lachuer,et al.  A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. , 2013, Cancer cell.

[13]  R. Dummer,et al.  Hypoxia contributes to melanoma heterogeneity by triggering HIF1α-dependent phenotype switching. , 2013, The Journal of investigative dermatology.

[14]  G. Boyle,et al.  Plasticity of melanoma in vivo: murine lesions resulting from Trp53, but not Cdk4 or Arf deregulation, display neural transdifferentiation , 2013, Pigment cell & melanoma research.

[15]  T. Tüting.  T cell immunotherapy for melanoma from bedside to bench to barn and back: how conceptual advances in experimental mouse models can be translated into clinical benefit for patients , 2013, Pigment cell & melanoma research.

[16]  Na‐Ra Han,et al.  The critical role of mast cell‐derived hypoxia‐inducible factor‐1α in human and mice melanoma growth , 2013, International Journal of Cancer.

[17]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[18]  A. Bovier,et al.  Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? , 2013, Nature Reviews Cancer.

[19]  Jun S. Song,et al.  Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. , 2013, Cancer cell.

[20]  K. Flaherty,et al.  Elucidating distinct roles for NF1 in melanomagenesis. , 2013, Cancer discovery.

[21]  B. J. Van den Eynde,et al.  Epithelial-Mesenchymal-Transition-Like and TGFβ Pathways Associated with Autochthonous Inflammatory Melanoma Development in Mice , 2012, PloS one.

[22]  J. Landsberg,et al.  Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation , 2012, Nature.

[23]  P. Dráber,et al.  Mast Cell Chemotaxis – Chemoattractants and Signaling Pathways , 2012, Front. Immun..

[24]  P. Bahadoran,et al.  Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells , 2012, Oncogene.

[25]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[26]  Feng-Chun Yang,et al.  Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression. , 2012, Annual review of pathology.

[27]  P. Bahadoran,et al.  Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny , 2011, Oncogene.

[28]  K. Hoek,et al.  Cancer stem cells versus phenotype‐switching in melanoma , 2010, Pigment cell & melanoma research.

[29]  U. Suter,et al.  Schwann Cell Precursors from Nerve Innervation Are a Cellular Origin of Melanocytes in Skin , 2009, Cell.

[30]  N. Ibrahim,et al.  Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice , 2009, Oncogene.

[31]  J. Reis-Filho,et al.  Oncogenic Braf induces melanocyte senescence and melanoma in mice. , 2009, Cancer cell.

[32]  R. DePinho,et al.  BRafV600E cooperates with Pten silencing to elicit metastatic melanoma , 2009, Nature Genetics.

[33]  R. Scolyer,et al.  Desmoplastic neurotropic melanoma , 2008, Cancer.

[34]  D. Schadendorf,et al.  Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. , 2006, Pigment cell research.

[35]  M. Barbacid,et al.  Rapid growth of invasive metastatic melanoma in carcinogen-treated hepatocyte growth factor/scatter factor-transgenic mice carrying an oncogenic CDK4 mutation. , 2006, The American journal of pathology.

[36]  L. Larue,et al.  Spatiotemporal gene control by the Cre‐ERT2 system in melanocytes , 2006, Genesis.

[37]  C. Pritchard,et al.  Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts. , 2005, Cancer research.

[38]  G. Kay,et al.  Tyrosinase‐Cre mice for tissue‐specific gene ablation in neural crest and neuroepithelial‐derived tissues , 2003, Genesis.

[39]  W. Mandemakers,et al.  The POU proteins Brn-2 and Oct-6 share important functions in Schwann cell development. , 2003, Genes & development.

[40]  D. Ribatti,et al.  Neovascularisation, expression of fibroblast growth factor-2, and mast cells with tryptase activity increase simultaneously with pathological progression in human malignant melanoma. , 2003, European Journal of Cancer.

[41]  D. Burns,et al.  Neurofibromas in NF1: Schwann Cell Origin and Role of Tumor Environment , 2002, Science.

[42]  Harris,et al.  Morphological and immunophenotypic variations in malignant melanoma , 2000, Histopathology.

[43]  Karlyne M. Reilly,et al.  Mouse models of tumor development in neurofibromatosis type 1. , 1999, Science.

[44]  J. Rosai,et al.  Metastatic malignant melanoma resembling malignant peripheral nerve sheath tumor: report of 16 cases. , 1999, The American journal of surgical pathology.

[45]  M. Barbacid,et al.  Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in β-islet cell hyperplasia , 1999, Nature Genetics.

[46]  A. Joyner,et al.  Multiple developmental defects in Engrailed-1 mutant mice: an early mid-hindbrain deletion and patterning defects in forelimbs and sternum. , 1994, Development.

[47]  D. Schadendorf,et al.  Amelanotic malignant melanoma presenting as malignant schwannoma , 1993, The British journal of dermatology.

[48]  R. Reed,et al.  Neurotropic melanoma: A variant of desmoplastic melanoma , 1979, The American journal of surgical pathology.

[49]  S. Dry,et al.  Malignant melanoma with neural differentiation: an exceptional case report and brief review of the pertinent literature. , 2014, The American Journal of dermatopathology.

[50]  D. Schadendorf,et al.  Mast cells in melanocytic tumours , 2004, Archives of Dermatological Research.